Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 22 | 2026 | 2602 | 2.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2026 | 1336 | 1.290 |
Why?
|
| Alopecia | 3 | 2018 | 41 | 1.060 |
Why?
|
| Quinolines | 5 | 2026 | 118 | 0.630 |
Why?
|
| Physical Therapy Modalities | 1 | 2018 | 51 | 0.530 |
Why?
|
| Scalp | 1 | 2017 | 59 | 0.490 |
Why?
|
| Hypothermia, Induced | 1 | 2017 | 172 | 0.450 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2022 | 280 | 0.430 |
Why?
|
| Brain Neoplasms | 4 | 2026 | 1306 | 0.380 |
Why?
|
| Aromatase Inhibitors | 2 | 2026 | 81 | 0.380 |
Why?
|
| Quality of Life | 4 | 2026 | 2082 | 0.380 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 86 | 0.350 |
Why?
|
| RANK Ligand | 1 | 2012 | 51 | 0.350 |
Why?
|
| Plasmacytoma | 1 | 2011 | 10 | 0.350 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1826 | 0.310 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 70 | 0.310 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 177 | 0.300 |
Why?
|
| Caregivers | 2 | 2025 | 598 | 0.270 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 475 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 981 | 0.230 |
Why?
|
| Neoplasms | 2 | 2018 | 3016 | 0.230 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 281 | 0.220 |
Why?
|
| Female | 27 | 2026 | 70963 | 0.220 |
Why?
|
| Pyridines | 1 | 2026 | 255 | 0.210 |
Why?
|
| Aged | 14 | 2026 | 21025 | 0.210 |
Why?
|
| Piperazines | 1 | 2026 | 265 | 0.210 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2026 | 222 | 0.200 |
Why?
|
| Estrogens | 1 | 2026 | 434 | 0.200 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 77 | 0.200 |
Why?
|
| Patient Preference | 1 | 2025 | 151 | 0.190 |
Why?
|
| Middle Aged | 17 | 2026 | 28601 | 0.190 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2022 | 37 | 0.180 |
Why?
|
| Social Support | 1 | 2025 | 370 | 0.180 |
Why?
|
| Humans | 31 | 2026 | 131163 | 0.180 |
Why?
|
| Estrogen Antagonists | 1 | 2022 | 91 | 0.180 |
Why?
|
| Stress, Psychological | 2 | 2025 | 536 | 0.180 |
Why?
|
| Proteogenomics | 1 | 2022 | 111 | 0.170 |
Why?
|
| Biomarkers, Tumor | 5 | 2023 | 1586 | 0.170 |
Why?
|
| Adenomyoepithelioma | 1 | 2019 | 1 | 0.150 |
Why?
|
| Cholecalciferol | 1 | 2019 | 20 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 400 | 0.140 |
Why?
|
| Trastuzumab | 3 | 2026 | 140 | 0.140 |
Why?
|
| Arthralgia | 1 | 2019 | 78 | 0.140 |
Why?
|
| Adult | 12 | 2026 | 31282 | 0.140 |
Why?
|
| Cryotherapy | 1 | 2018 | 16 | 0.140 |
Why?
|
| Hair Diseases | 1 | 2018 | 14 | 0.140 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2018 | 7 | 0.140 |
Why?
|
| STAT5 Transcription Factor | 1 | 2018 | 93 | 0.130 |
Why?
|
| Paclitaxel | 2 | 2015 | 130 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 251 | 0.130 |
Why?
|
| Docosahexaenoic Acids | 1 | 2018 | 67 | 0.130 |
Why?
|
| Radiotherapy | 1 | 2018 | 119 | 0.130 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2017 | 17 | 0.130 |
Why?
|
| Bridged-Ring Compounds | 1 | 2017 | 19 | 0.130 |
Why?
|
| Janus Kinase 2 | 1 | 2018 | 138 | 0.130 |
Why?
|
| Anthracyclines | 1 | 2017 | 47 | 0.120 |
Why?
|
| Taxoids | 1 | 2017 | 73 | 0.120 |
Why?
|
| Receptors, Androgen | 1 | 2019 | 408 | 0.120 |
Why?
|
| Primary Prevention | 1 | 2017 | 183 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2015 | 570 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 75 | 0.100 |
Why?
|
| Neoplasm Metastasis | 3 | 2025 | 713 | 0.100 |
Why?
|
| Fatal Outcome | 2 | 2011 | 352 | 0.100 |
Why?
|
| Jejunal Neoplasms | 1 | 2012 | 5 | 0.090 |
Why?
|
| Jejunal Diseases | 1 | 2012 | 11 | 0.090 |
Why?
|
| Phyllodes Tumor | 1 | 2012 | 9 | 0.090 |
Why?
|
| Denosumab | 1 | 2012 | 13 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2021 | 3711 | 0.090 |
Why?
|
| Risk Factors | 3 | 2021 | 11074 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2015 | 310 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 789 | 0.090 |
Why?
|
| Intussusception | 1 | 2012 | 54 | 0.090 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2011 | 101 | 0.080 |
Why?
|
| Mastectomy, Segmental | 2 | 2022 | 37 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2026 | 12936 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2022 | 156 | 0.080 |
Why?
|
| Qualitative Research | 2 | 2025 | 730 | 0.080 |
Why?
|
| Bone Marrow | 1 | 2011 | 317 | 0.070 |
Why?
|
| Apoptosis | 3 | 2018 | 1827 | 0.070 |
Why?
|
| Skin | 1 | 2011 | 545 | 0.070 |
Why?
|
| Breast | 2 | 2019 | 215 | 0.060 |
Why?
|
| Administration, Intravaginal | 1 | 2026 | 10 | 0.060 |
Why?
|
| Maytansine | 1 | 2026 | 6 | 0.060 |
Why?
|
| Dyspareunia | 1 | 2026 | 10 | 0.060 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 160 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 1287 | 0.060 |
Why?
|
| Prognosis | 3 | 2022 | 4886 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2005 | 88 | 0.050 |
Why?
|
| Vagina | 1 | 2026 | 208 | 0.050 |
Why?
|
| Diarrhea | 1 | 2026 | 301 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2026 | 348 | 0.050 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 94 | 0.050 |
Why?
|
| Survival Rate | 2 | 2019 | 2114 | 0.050 |
Why?
|
| Safety-net Providers | 1 | 2025 | 93 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 4066 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2065 | 0.050 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 19 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 405 | 0.050 |
Why?
|
| Carboplatin | 1 | 2022 | 79 | 0.050 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2022 | 29 | 0.050 |
Why?
|
| Quinazolines | 1 | 2023 | 176 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 639 | 0.050 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2022 | 51 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 6797 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 597 | 0.040 |
Why?
|
| Palliative Care | 1 | 2025 | 443 | 0.040 |
Why?
|
| Oxazepines | 1 | 2019 | 1 | 0.040 |
Why?
|
| Phenylthiohydantoin | 1 | 2019 | 15 | 0.040 |
Why?
|
| Glioma | 1 | 2005 | 494 | 0.040 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2019 | 40 | 0.040 |
Why?
|
| Capecitabine | 1 | 2019 | 20 | 0.040 |
Why?
|
| Benzamides | 1 | 2019 | 127 | 0.040 |
Why?
|
| Nitriles | 1 | 2019 | 163 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2019 | 358 | 0.040 |
Why?
|
| Craniotomy | 1 | 2019 | 102 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 159 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 712 | 0.040 |
Why?
|
| Pimozide | 1 | 2018 | 7 | 0.030 |
Why?
|
| Proteomics | 1 | 2022 | 615 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 219 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 387 | 0.030 |
Why?
|
| Hyperprolactinemia | 1 | 2018 | 23 | 0.030 |
Why?
|
| Pigmentation Disorders | 1 | 2018 | 22 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 732 | 0.030 |
Why?
|
| Risperidone | 1 | 2018 | 59 | 0.030 |
Why?
|
| Mass Screening | 1 | 2023 | 822 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 711 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2200 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 732 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 631 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2019 | 448 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 338 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 386 | 0.030 |
Why?
|
| Animals | 2 | 2018 | 33912 | 0.030 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2015 | 9 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 85 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 1445 | 0.030 |
Why?
|
| Albumins | 1 | 2015 | 87 | 0.030 |
Why?
|
| Cell Count | 1 | 2015 | 212 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 375 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 633 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1626 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 3385 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2018 | 768 | 0.020 |
Why?
|
| Biopsy | 1 | 2015 | 1239 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1801 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 426 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1928 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2018 | 4686 | 0.020 |
Why?
|
| Male | 3 | 2025 | 64957 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 3061 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 5063 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5196 | 0.020 |
Why?
|
| Brain | 1 | 2019 | 3175 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 10103 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2005 | 21 | 0.010 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2005 | 33 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2005 | 157 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 576 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 480 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 18301 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 3748 | 0.010 |
Why?
|